Anika Therapeutics (ANIK) 2026 CG Musculoskeletal Conference summary

Business Overview and Strategy

• Focus on differentiated hyaluronic acid-based technologies for joint preservation, OA pain management, and regenerative medicine, with a 33-year track record and robust innovation pipeline.

• Strategy centers on accelerating growth via commercial momentum, advancing the new product pipeline, and strengthening operational discipline.

• Strong balance sheet with $57.5M in cash at end of 4Q 2025, no debt, and consistent profitability and cash flow, enabling continued investment in new product launches without raising capital.

• Commercial channel revenue grew from $26M in 2021 to $48M in 2025, with a 17% CAGR over five years, and is projected to maintain strong double-digit growth.

• Three-pronged strategy includes driving top-line growth, advancing the product pipeline, and maintaining operational discipline.

Product Portfolio and Market Position

• Core portfolio includes OA pain management products (Orthovisc, Monovisc, Cingal) and regenerative solutions (Integrity, Hyalofast), with a market-leading US viscosupplement portfolio supported by a partnership with J&J MedTech.

• Integrity Implant System launched in 2023, achieved $2M in 2024 and $6M in 2025 sales, doubling revenue and exceeding expectations, with superior strength and regenerative capacity.

• Hyalofast, a single-stage, off-the-shelf, resorbable scaffold for cartilage repair, sold in 35+ countries with over 40,000 implants, US PMA submitted, and US launch planned for Q4 2027.

• Cingal, a next-generation OA pain product, targets a $1B market, has shown statistically superior pain reduction and durability, with over 1 million doses sold OUS and NDA filing expected in 2026.

• Proprietary HA technology platform underpins both pain management and regenerative solutions, offering unique advantages in healing and tissue repair.

Clinical and Regulatory Updates

• Hyalofast US PMA filing completed third module; secondary endpoints met in clinical trials, supporting ongoing FDA discussions, with US launch planned for 2027.

• Cingal completed three phase 3 trials, showing statistical significance; NDA filing in the US pending completion of a bioequivalence study, expected in 2026.

• Integrity and Hyalofast leverage HYAFF technology, with plans for further launches and updates as regulatory milestones are reached.